Antidepressants and Weight Gain

Home > Depression > Antidepressants and Weight Gain

Antidepressants differ in how much weight they add, and for most of them the differences are small. In a 2024 analysis of electronic health records from 183,118 adults at eight U.S. health systems between 2010 and 2019, six-month weight gain relative to sertraline was 0.41 kg higher with escitalopram, 0.37 kg higher with paroxetine, 0.34 kg higher with duloxetine, and 0.22 kg lower with bupropion (Petimar and colleagues, Annals of Internal Medicine, 2024). In pounds, the spread between the medication with the most gain and the one with the least was about 1.4 lb at six months.

That spread widened with time. At 24 months the bupropion group weighed about 0.91 kg (2 lb) less than the sertraline group, and about 2.3 kg (5 lb) less among patients who kept taking the medication. Weight is the side effect patients ask me about before almost any other, and for most medications the measured numbers are smaller than the fear. The exceptions, mirtazapine and to a lesser extent paroxetine, have earned their reputation.

Real-world data rank the common antidepressants

The 2024 cohort is the largest head-to-head comparison available, and it was designed to mimic a randomized trial using routine clinical data. Patients had a mean starting weight of 84 kg (185 lb) and a mean BMI of 29.4. The six-month differences from sertraline were:

• Escitalopram: +0.41 kg (about 0.9 lb)
• Paroxetine: +0.37 kg (about 0.8 lb)
• Duloxetine: +0.34 kg (about 0.7 lb)
• Venlafaxine: +0.17 kg (about 0.4 lb)
• Citalopram: +0.12 kg (about 0.3 lb)
• Fluoxetine: −0.07 kg (no meaningful difference)
• Bupropion: −0.22 kg (about 0.5 lb less)

Averages understate the tails. Escitalopram, paroxetine, and duloxetine were associated with a 10% to 15% higher risk of gaining at least 5% of body weight by six months, while bupropion was associated with a 15% lower risk. For the average patient in that cohort, 5% is about 4.2 kg, or 9 lb.

An earlier record-based study reached a similar ranking. Among 22,610 adults in a New England health system followed for 12 months after a first prescription, bupropion, amitriptyline, and nortriptyline were associated with less weight gain than citalopram, and the authors called the differences modest (Blumenthal and colleagues, JAMA Psychiatry, 2014).

Both studies are observational. Adherence in the 2024 cohort fell from 28% to 41% at six months to 4% to 5% at 24 months, and weights came from routine visits. The results cannot establish causal relationships, and the medication management decision for any one patient still rests on that patient's history.

The differences are measured in a few pounds

A 2 lb difference between bupropion and sertraline over two years is real and reproducible. It is also small enough that a single weigh-in cannot detect it. The 5% threshold, roughly 9 lb for an average adult, is the cutoff the cohort studies used for clinically meaningful gain.

Population data put the same finding in different units. In a UK primary-care cohort of 294,719 adults followed from 2004 to 2014, new episodes of 5% or greater weight gain occurred at 11.2 per 100 person-years among people prescribed antidepressants and 8.1 per 100 person-years among those who were not, an adjusted rate ratio of 1.21 (Gafoor and colleagues, BMJ, 2018). In the second year of treatment, 27 people needed to be treated for one year for one additional episode of 5% weight gain, and the elevated risk persisted for at least six years. The authors cautioned that residual confounding might inflate those associations, since depression severe enough to treat is itself associated with weight change.

Mirtazapine and paroxetine stand apart

Mirtazapine is the clearest outlier. In the six-week U.S. trials summarized in its FDA label, increased appetite was reported by 17% of patients on mirtazapine versus 2% on placebo, and 7.5% of mirtazapine-treated patients gained at least 7% of their body weight compared with none on placebo. In the pooled premarketing studies, 8% of patients discontinued because of weight gain. A 2011 Cochrane review of 29 randomized trials covering 4,974 adults found mirtazapine more likely than SSRIs to cause weight gain, increased appetite, and somnolence, less likely to cause nausea or sexual dysfunction, and more effective at two weeks (odds ratio 1.57) (Watanabe and colleagues, Cochrane Database of Systematic Reviews, 2011).

Those properties are why mirtazapine exists in my practice. For a patient who has stopped eating and cannot sleep, appetite and sedation are the treatment. For a patient already struggling with weight, I usually look elsewhere first.

Paroxetine's label and its long-term data disagree. The Paxil prescribing information reports that patients in controlled trials had minimal weight loss, about 1 pound, on average. Those trials were short. In a randomized comparison of 284 adults treated for 26 to 32 weeks, paroxetine produced a significant weight increase, fluoxetine a modest nonsignificant decrease, and sertraline a modest nonsignificant increase, with significantly more paroxetine-treated patients gaining 7% or more (Fava and colleagues, Journal of Clinical Psychiatry, 2000). A meta-analysis of 116 studies placed amitriptyline, mirtazapine, and paroxetine in the higher-gain group and found some weight loss with fluoxetine and bupropion (Serretti and Mandelli, Journal of Clinical Psychiatry, 2010).

Depression itself moves weight in both directions

Change in appetite or weight, in either direction, is one of the diagnostic criteria for a major depressive episode. Some patients lose weight before they ever see a prescriber; others gain it. When the depression lifts, appetite returns and activity changes, and some of what gets attributed to the pill likely reflects recovery.

The longer arc matters too. A meta-analysis of 15 longitudinal studies covering 58,745 people found that obesity at baseline raised the odds of later depression (odds ratio 1.55) and that depression at baseline raised the odds of later obesity (odds ratio 1.58) (Luppino and colleagues, Archives of General Psychiatry, 2010). Many people starting an antidepressant were already on a trajectory toward weight gain before the first dose.

Patients notice this. The question I hear most often runs, "I started sertraline four months ago, I feel like myself again, and I've gained six pounds. Do I need to stop?" My answer is usually no. Six pounds in four months is within the range that recovery alone can produce, sertraline sits in the middle of the pack, and the depression usually cost that person far more than six pounds. What follows is tracking weight at each visit, with a change in plan only if the gain continues.

The medication effect, when present, likely operates through histamine and serotonin receptor pathways that promote appetite, strongest for mirtazapine and reversed for bupropion (Gill and colleagues, Obesity, 2020). That heterogeneity in mechanism is why switching across classes can help more than switching within one.

Early loss, later gain: the time course matters

SSRIs often produce a small weight loss in the first weeks, driven by nausea and reduced appetite, and the gain comes later. The Paxil label's 1 lb average loss and the 26-week trial's significant gain describe the same drug at different points in time, and Serretti and Mandelli found across 116 studies that effects on body weight generally became more evident in the long term.

The 2024 cohort adds a wrinkle. The escitalopram difference from sertraline held at 0.41 kg at both 6 and 12 months, while the duloxetine and venlafaxine differences reversed sign by 24 months. With adherence at 4% to 5% by then, the authors could not separate a true late effect from the fact that most people were no longer taking the medication being compared.

Accordingly, I weigh patients at the first visit and again at three and six months, and I ask about appetite at every medication visit. A gain in the first six weeks is more likely to be recovery; a gain that continues past six months on a stable dose is more likely to be the drug.

What prescribers do about it

Choose with weight in mind from the start. When weight is a leading concern and the clinical picture fits, bupropion or fluoxetine are reasonable first choices. In the short-term trials in its FDA label, bupropion sustained-release at 300 mg per day was associated with weight loss of 5 lb or more in 14% of patients versus 6% on placebo. Bupropion is contraindicated in seizure disorders and in current or past anorexia nervosa or bulimia, and I choose it less often when anxiety is the dominant symptom. The non-stimulant ADHD medication page covers its off-label use in that setting.

Switch when the gain is clearly attributable. Moving from mirtazapine, paroxetine, or amitriptyline to a lower-gain option is the switch most likely to produce a visible change. Switching between two SSRIs that differ by a few tenths of a kilogram usually trades a known response for an unknown one. Cross-tapers and timing are planned with the prescriber.

Add bupropion rather than stop the SSRI. Combining bupropion with an SSRI is a common strategy when response is partial, and bupropion's own weight profile makes it a logical add-on when weight is also a concern. The weight-specific evidence for the combination is thinner than for bupropion alone, so I frame it as an evidence-supported augmentation that may also help weight.

Metformin has thin evidence here. Its controlled data come from antipsychotic-induced weight gain, where a meta-analysis of 12 placebo-controlled trials in 743 patients found a mean weight reduction of 3.27 kg versus placebo (de Silva and colleagues, BMC Psychiatry, 2016). For antidepressant-associated gain the trial evidence is sparse, so I treat metformin as an off-label option for patients who also take an antipsychotic or have prediabetes, in coordination with primary care.

Lifestyle changes operate on the same scale as the drug effect. A medication effect of 1 to 2 lb over a year is within reach of ordinary changes in diet, alcohol, and activity, and CBT can address the behavioral side alongside the medication.

Stopping an effective antidepressant for a small weight change usually costs more than it saves

Across 31 randomized trials of 4,410 people who had responded to an antidepressant, 41% of those switched to placebo relapsed, compared with 18% of those who continued, a 70% reduction in the odds of relapse (Geddes and colleagues, Lancet, 2003). For a patient weighing a 2 lb gain against a roughly one-in-four absolute increase in relapse risk, the arithmetic rarely favors stopping. Depression also carries its own metabolic cost, since recurrent depression is associated with later obesity, so stopping a medication to protect one's weight may over years do the opposite.

Importantly, none of this means a patient has to accept weight gain as the price of treatment. The sequence is: confirm the gain is real and attributable, then switch or augment, then consider stopping, and never abruptly. When depression has failed two or more adequate trials, the question changes from weight to efficacy; see treatment-resistant depression and medication vs therapy vs both.

Adolescents and children need closer weight monitoring

The pediatric data cut in both directions. In the one 8-week trial of mirtazapine in pediatric patients described in its FDA label, 49% of treated patients gained at least 7% of their body weight compared with 5.7% on placebo, with a mean gain of 4 kg versus 1 kg. The label states that safety and effectiveness in pediatric depression have not been established, and that number is a large part of why I rarely use it in adolescents.

SSRIs in young people tend the other way. The paroxetine label notes that decreased appetite and weight loss have been observed with SSRIs in children and adolescents and advises regular monitoring of weight and growth. I plot height and weight on a growth chart at every visit, and a flattening curve is a reason to reassess. See the adolescent psychiatry and child psychiatry pages.

Who this practice fits, and when to go elsewhere

This fits adults and adolescents who are doing well on an antidepressant and have gained weight they want addressed without losing the response. It also fits patients choosing a first antidepressant who have diabetes, prediabetes, or a family history that makes weight a clinical priority. A second opinion on a regimen that has drifted to three or four medications, several of which add weight, is a common reason people come in.

Some situations belong elsewhere. A current or past eating disorder changes the calculus, including the safety of bupropion, and warrants a program with eating-disorder expertise. Rapid weight gain with new edema, thirst, or blurred vision needs medical evaluation first. Patients whose main goal is weight loss, with mood stable, are better served by primary care or obesity medicine, and I will say so at the first visit. An active suicidal crisis needs an emergency department today.

Cost and booking

Initial evaluations run 60 to 90 minutes and include a medication history with doses and dates, a weight history, and any prior labs. The practice is out-of-network with all insurance plans. You pay directly and receive a superbill to submit for reimbursement; many NYC plans with out-of-network benefits reimburse a meaningful share once the deductible is met. The numbers are at fees and out-of-network costs, and you can check your out-of-network benefits before the first visit.

Bring a list of every antidepressant you have taken, with dose, duration, and what happened to your weight. Schedule a consultation or call (646) 893-4309.

Related

Depression · Medication management · Medication vs therapy vs both · Treatment-resistant depression · What type of doctor treats depression · Second opinions · Adolescent psychiatry · Generalized anxiety disorder · Emotional blunting on antidepressants · Antidepressant sexual side effects · Depression with ADHD: combining medications · Anxiety medication options · How long antidepressants take to work · Lexapro vs Zoloft · SSRIs for teens · Stopping antidepressants · Wellbutrin vs SSRIs

When Depression Becomes an Emergency

Stopping an antidepressant on your own because of weight gain is a common path back into a depressive episode, and the weeks after any medication change are a time to watch mood closely. Suicidal thoughts without immediate crisis still warrant same-day or next-day psychiatric evaluation.

Frequently Asked Questions

Which antidepressant causes the least weight gain?

Bupropion. In the 2024 cohort of 183,118 adults, bupropion users weighed about 0.22 kg (half a pound) less than sertraline users at six months and about 0.91 kg (2 lb) less at 24 months, and they were 15% less likely to gain 5% of their body weight. Bupropion is contraindicated in seizure disorders and in current or past anorexia or bulimia, so it suits some patients and not others.

Which antidepressant causes the most weight gain?

Mirtazapine, by a clear margin. In the six-week trials in its FDA label, 7.5% of patients gained at least 7% of their body weight compared with none on placebo, and increased appetite was reported by 17% versus 2%. Among the SSRIs, paroxetine carries the highest risk in long-term trials, followed by escitalopram in real-world data. Amitriptyline, an older tricyclic, also adds weight.

How much weight do people actually gain on an SSRI?

Less than most patients expect. In the 2024 health-system cohort, the differences between the common SSRIs and sertraline at six months were under half a kilogram, about 1 lb. The more useful figure is the share of people who gain 5% of body weight, roughly 9 lb for an average adult: escitalopram, paroxetine, and duloxetine raised that risk by 10% to 15% relative to sertraline. Averages hide heterogeneity; some people gain much more.

Why did I lose weight at first and then gain it?

Both patterns are documented. The paroxetine label reports about a pound of loss in short controlled trials, yet over 26 to 32 weeks paroxetine produced significant weight gain in a randomized comparison. Early loss likely reflects nausea and reduced appetite in the first weeks; later gain likely reflects a mix of the medication, recovery of appetite as depression lifts, and the weight trajectory depression had already set.

Should I stop my antidepressant because of weight gain?

Usually no, and never abruptly. Across 31 randomized trials, people who stopped an antidepressant after responding relapsed at 41% versus 18% for those who continued. A gain of a few pounds rarely outweighs that. What I do instead is confirm the gain is real and attributable, then consider a lower-gain alternative, adding bupropion, or lifestyle changes. Stopping is a decision made with the prescriber, with a plan.

Does metformin help with antidepressant weight gain?

The controlled evidence is for antipsychotic-induced weight gain, where a meta-analysis of 12 placebo-controlled trials found about 3.3 kg of weight reduction with metformin. For antidepressants the trial evidence is thin, so metformin is an off-label option with little direct support. I consider it mainly when an antipsychotic is also on board or when prediabetes is present, in coordination with primary care.

Sources

1. Petimar J, Young JG, Yu H, et al. Medication-induced weight change across common antidepressant treatments: a target trial emulation study. Ann Intern Med. 2024;177(8):993–1003. PMID 38950403
2. Blumenthal SR, Castro VM, Clements CC, et al. An electronic health records study of long-term weight gain following antidepressant use. JAMA Psychiatry. 2014;71(8):889–896. PMID 24898363
3. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study. BMJ. 2018;361:k1951. PMID 29793997
4. Serretti A, Mandelli L. Antidepressants and body weight (review and meta-analysis of 116 studies). J Clin Psychiatry. 2010;71(10):1259–1272. PMID 21062615
5. Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011;(12):CD006528. PMID 22161405
6. Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000;61(11):863–867. PMID 11105740
7. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220–229. PMID 20194822
8. Gill H, Gill B, El-Halabi S, et al. Antidepressant medications and weight change: a narrative review. Obesity (Silver Spring). 2020;28(11):2064–2072. PMID 33022115
9. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653–661. PMID 12606176
10. de Silva VA, Suraweera C, Ratnatunga SS, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341. PMID 27716110
11. U.S. Food and Drug Administration. Remeron (mirtazapine) tablets and RemeronSolTab prescribing information. Revised 2020. FDA label (PDF)
12. U.S. Food and Drug Administration. Paxil (paroxetine hydrochloride) tablets and oral suspension prescribing information. Revised 2017. FDA label (PDF)
13. U.S. Food and Drug Administration. Wellbutrin XL (bupropion hydrochloride extended-release) tablets prescribing information. Revised 2025. FDA label (PDF)